Cargando…

Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial

BACKGROUND: It remains unclear whether patients’ self‐perceptions of symptoms at baseline clinically impact the prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with the first‐line cetuximab and standard chemotherapy. METHODS: The...

Descripción completa

Detalles Bibliográficos
Autores principales: Ooki, Akira, Morita, Satoshi, Iwamoto, Shigeyoshi, Hara, Hiroki, Tanioka, Hiroaki, Satake, Hironaga, Kataoka, Masato, Kotaka, Masahito, Kagawa, Yoshinori, Nakamura, Masato, Shingai, Tatsushi, Ishikawa, Masashi, Miyake, Yasuhiro, Suto, Takeshi, Hashiguchi, Yojiro, Yabuno, Taichi, Sakamoto, Junichi, Tsuji, Akihito, Ando, Masahiko, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050093/
https://www.ncbi.nlm.nih.gov/pubmed/31962002
http://dx.doi.org/10.1002/cam4.2826
_version_ 1783502568883748864
author Ooki, Akira
Morita, Satoshi
Iwamoto, Shigeyoshi
Hara, Hiroki
Tanioka, Hiroaki
Satake, Hironaga
Kataoka, Masato
Kotaka, Masahito
Kagawa, Yoshinori
Nakamura, Masato
Shingai, Tatsushi
Ishikawa, Masashi
Miyake, Yasuhiro
Suto, Takeshi
Hashiguchi, Yojiro
Yabuno, Taichi
Sakamoto, Junichi
Tsuji, Akihito
Ando, Masahiko
Yamaguchi, Kensei
author_facet Ooki, Akira
Morita, Satoshi
Iwamoto, Shigeyoshi
Hara, Hiroki
Tanioka, Hiroaki
Satake, Hironaga
Kataoka, Masato
Kotaka, Masahito
Kagawa, Yoshinori
Nakamura, Masato
Shingai, Tatsushi
Ishikawa, Masashi
Miyake, Yasuhiro
Suto, Takeshi
Hashiguchi, Yojiro
Yabuno, Taichi
Sakamoto, Junichi
Tsuji, Akihito
Ando, Masahiko
Yamaguchi, Kensei
author_sort Ooki, Akira
collection PubMed
description BACKGROUND: It remains unclear whether patients’ self‐perceptions of symptoms at baseline clinically impact the prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with the first‐line cetuximab and standard chemotherapy. METHODS: The data were collected from a prospective trial that assessed the relationships between quality of life (QOL), treatment efficacy, and adverse events (AEs). RESULTS: The analysis of 137 mCRC patients revealed a significant association between the presence of baseline tumor‐related symptoms and a lower overall survival (OS) compared to the absence of symptoms (HR, 2.49; 95% CI, 1.37‐4.62; P = .003). The asymptomatic responders had favorable outcomes compared to the symptomatic nonresponders (2‐year OS rates: 83.6% and 35.9%, respectively), while the symptomatic responders had similar outcomes to the asymptomatic nonresponders. The median postprogression survival differed significantly: 10.2 months for the symptomatic patients and 15.9 months for the asymptomatic patients (HR, 2.29; 95% CI, 1.25‐4.29, P = .008). The objective response rates and patient toxicity profiles were similar irrespective of the severity of baseline symptoms. CONCLUSION: Baseline symptoms were associated with worse OS but not with impaired treatment efficacy or more frequent AEs in mCRC patients treated with cetuximab in addition to chemotherapy.
format Online
Article
Text
id pubmed-7050093
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70500932020-03-05 Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial Ooki, Akira Morita, Satoshi Iwamoto, Shigeyoshi Hara, Hiroki Tanioka, Hiroaki Satake, Hironaga Kataoka, Masato Kotaka, Masahito Kagawa, Yoshinori Nakamura, Masato Shingai, Tatsushi Ishikawa, Masashi Miyake, Yasuhiro Suto, Takeshi Hashiguchi, Yojiro Yabuno, Taichi Sakamoto, Junichi Tsuji, Akihito Ando, Masahiko Yamaguchi, Kensei Cancer Med Clinical Cancer Research BACKGROUND: It remains unclear whether patients’ self‐perceptions of symptoms at baseline clinically impact the prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with the first‐line cetuximab and standard chemotherapy. METHODS: The data were collected from a prospective trial that assessed the relationships between quality of life (QOL), treatment efficacy, and adverse events (AEs). RESULTS: The analysis of 137 mCRC patients revealed a significant association between the presence of baseline tumor‐related symptoms and a lower overall survival (OS) compared to the absence of symptoms (HR, 2.49; 95% CI, 1.37‐4.62; P = .003). The asymptomatic responders had favorable outcomes compared to the symptomatic nonresponders (2‐year OS rates: 83.6% and 35.9%, respectively), while the symptomatic responders had similar outcomes to the asymptomatic nonresponders. The median postprogression survival differed significantly: 10.2 months for the symptomatic patients and 15.9 months for the asymptomatic patients (HR, 2.29; 95% CI, 1.25‐4.29, P = .008). The objective response rates and patient toxicity profiles were similar irrespective of the severity of baseline symptoms. CONCLUSION: Baseline symptoms were associated with worse OS but not with impaired treatment efficacy or more frequent AEs in mCRC patients treated with cetuximab in addition to chemotherapy. John Wiley and Sons Inc. 2020-01-21 /pmc/articles/PMC7050093/ /pubmed/31962002 http://dx.doi.org/10.1002/cam4.2826 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Ooki, Akira
Morita, Satoshi
Iwamoto, Shigeyoshi
Hara, Hiroki
Tanioka, Hiroaki
Satake, Hironaga
Kataoka, Masato
Kotaka, Masahito
Kagawa, Yoshinori
Nakamura, Masato
Shingai, Tatsushi
Ishikawa, Masashi
Miyake, Yasuhiro
Suto, Takeshi
Hashiguchi, Yojiro
Yabuno, Taichi
Sakamoto, Junichi
Tsuji, Akihito
Ando, Masahiko
Yamaguchi, Kensei
Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
title Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
title_full Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
title_fullStr Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
title_full_unstemmed Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
title_short Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
title_sort patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of phase ii quack trial
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050093/
https://www.ncbi.nlm.nih.gov/pubmed/31962002
http://dx.doi.org/10.1002/cam4.2826
work_keys_str_mv AT ookiakira patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT moritasatoshi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT iwamotoshigeyoshi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT harahiroki patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT taniokahiroaki patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT satakehironaga patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT kataokamasato patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT kotakamasahito patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT kagawayoshinori patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT nakamuramasato patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT shingaitatsushi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT ishikawamasashi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT miyakeyasuhiro patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT sutotakeshi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT hashiguchiyojiro patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT yabunotaichi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT sakamotojunichi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT tsujiakihito patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT andomasahiko patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial
AT yamaguchikensei patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial